The research study used 530 men, from the United States, Europe, and Canada, all with premature ejaculation.
Of this total number, 358 men gave themselves three quick sprays of PSD502 onto the head of their penis five minutes before having sex. Just before sex they wiped the spray off their penis.
The PSD502 spray contains two common topical painkillers. They are lidocaine and prilocaine. The spray is made by Shionogi Pharma Inc., a U.S.-based group company of Shionogi & Co., Ltd., which is headquartered in Atlanta, Georgia, U.S.A.
The other men used a spray of placebo (an inactive substance), as a control group for the study. Both groups did not know which product they were being given.
They used the product for three months, for a total of about 23,000 doses.
Page two continues with the results of the study.
Generally, for men who did not use the PSD502, the time of premature ejaculation, on average, was approximately 0.5 minute (30 seconds).
According to WebMD, premature ejaculation occurs when ejaculation occurs within one minute of vaginal penetration.
The organization states that up to 30% of men suffer some degree of premature ejaculation. And, premature ejaculation, according to WebMD, is the top sexual health problem for men in the United States.
Dr. Ira D. Sharlip headed the study of PSD502 and premature ejaculation. Dr. Sharlip is a clinical professor of urology (and senior physician diplomate of urology) at the University of California, San Francisco. The study was funded by Shionogi Pharma Inc., which makes the PSD502 spray.
According to the WebMD article 'New Drug Spray May Help Premature Ejaculation,' Dr. Sharlip presented his study's findings at the 2010 annual meeting of the American Urological Association (AUA), which was held in San Francisco, California.
Page three continues with comments from Dr. Sharlip.
The WebMD article also stated that unproven products, such as 'Stay Erect' and 'Play Longer' are on the market. Thus, PSD502 is the only product that has been scientifically studied to actually extend premature ejaculation in men.
Dr. Sharlip reported that at the beginning of the study the average time 'from penetration to ejaculation' was 36 seconds for both groups.
At the end of the study, three months later, the PSD502 group had increased this time to 3.3 minutes, while the control group was still under 1 minute.
The WebMD article stated, 'A stopwatch held by the man or his partner was used to calculate the times. 'Talk about distracting,'.... 'But that's one of the strengths of the study; they got real data, not just men reporting back they think they lasted longer after using the medication.'"
Also, 'The men getting PSD502 also reported better ejaculatory control and overall satisfaction with their sexual experience than the placebo recipients.'
Page four concludes with the future of PSD502, along with further information about the study.
However, the product shows promise in delaying premature ejaculation. Before being offered to the public, the U.S. Food and Drug Administration (FDA) will have to approve its use. Such approval is being sought by Shionogi,.
For additional information on this study, please read the June 1, 2010 EurekAlert article 'Pivotal data for the investigational treatment PSD502 for primary premature ejaculation.'